Over the last decade, the FDA has approved five new medications for the treatment of obesity. The latest edition, semaglutide, published impressive weight loss results and we are just beginning. There is a rich pipeline of future anti-obesity medications (AOM) that will give provides excellent options for both the treatment of obesity and of the obesity-related diseases. This session will start with reviewing some of the common pathophysiologic pathways that current and future AOM s target then discuss emerging and future prospects of pharmacotherapy for the treatment of obesity. Recorded during Overcoming Obesity 2022. CME/CE Expiration Date: 11/1/25 *The expiration date listed above is the last day CME/CE credit can be claimed for this specific presentation.
- Provider:Obesity Medicine Association
- Activity Link: https://academy.obesitymedicine.org/node/616
- Start Date: 2023-05-08 05:00:00
- End Date: 2023-05-08 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 1.0 hours
- Commercial Support: No
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: Variable
- Measured Outcome: Learner Competence
- Provider Ship: Directly Provided
- Registration: Open to all